Research Analysts Set Expectations for DNLI FY2026 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Analysts at HC Wainwright raised their FY2026 earnings estimates for Denali Therapeutics in a research note issued to investors on Tuesday, January 7th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.58) per share for the year, up from their previous estimate of ($0.69). HC Wainwright has a “Buy” rating and a $87.00 price objective on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2027 earnings at $1.82 EPS.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period last year, the business earned ($0.72) earnings per share.

A number of other research firms have also recently issued reports on DNLI. Stifel Nicolaus raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Monday, December 16th. Raymond James reissued a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. JPMorgan Chase & Co. cut their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday. William Blair started coverage on Denali Therapeutics in a report on Friday, January 3rd. They set an “outperform” rating for the company. Finally, Robert W. Baird assumed coverage on Denali Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $31.00 price target on the stock. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.91.

Denali Therapeutics Price Performance

NASDAQ DNLI opened at $21.25 on Thursday. Denali Therapeutics has a one year low of $14.56 and a one year high of $33.33. The firm has a market cap of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39. The stock’s 50-day moving average is $24.34 and its 200-day moving average is $24.88.

Institutional Trading of Denali Therapeutics

Hedge funds have recently made changes to their positions in the business. MONECO Advisors LLC grew its stake in Denali Therapeutics by 4.6% in the 3rd quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock valued at $265,000 after buying an additional 400 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after acquiring an additional 580 shares during the period. CWM LLC grew its position in shares of Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after purchasing an additional 654 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after purchasing an additional 920 shares during the period. Finally, Quest Partners LLC acquired a new stake in Denali Therapeutics during the 3rd quarter worth approximately $73,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, Director Steve E. Krognes sold 3,339 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the completion of the sale, the director now owns 25,757 shares in the company, valued at $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Alexander O. Schuth sold 15,558 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the transaction, the insider now owns 178,066 shares in the company, valued at $5,325,954.06. This represents a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 104,518 shares of company stock worth $2,576,982 over the last ninety days. 7.90% of the stock is currently owned by corporate insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.